Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.05 is 68% above its 2-year average of 0.03, around the middle of its 2-year range (-0.01–0.13).
As of the fiscal period ended Tuesday, June 30, 2026. 36.58% above its 12-month average of 0.04.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.05.
DEBT TO EQUITY RATIO
0.05
DEBT TO EQUITY RATIO AVG TTM
0.04
DEBT TO EQUITY RATIO AVG 3Y
N/A
DEBT TO EQUITY RATIO AVG 5Y
N/A
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+36.58%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11
median of 774 covered companies
CURRENT VS SECTOR MEDIAN
-52.56%
vs the sector median at left
Market Cap
$321.76M
Debt to Equity Ratio
6.11
TTM Avg
4.48
3Y Avg
2.31
5Y Avg
1.55
Market Cap
$329.37M
Debt to Equity Ratio
0.12
TTM Avg
0.17
3Y Avg
0.10
5Y Avg
0.07
Market Cap
$330.19M
Debt to Equity Ratio
5.93
TTM Avg
1.11
3Y Avg
0.80
5Y Avg
2.27
Market Cap
$318.43M
Debt to Equity Ratio
0.23
TTM Avg
0.27
3Y Avg
0.28
5Y Avg
0.22
Market Cap
$309.19M
Debt to Equity Ratio
0.00
TTM Avg
0.01
3Y Avg
0.70
5Y Avg
0.51
Market Cap
$344.04M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CapsoVision, Inc. (CV) | $324.76M | 0.05 | 0.04 | N/A | N/A |
| Avita Medical Inc. (RCEL)vs › | $322.71M | N/A | 5.54 | 2.78 | 1.86 |
| Sanara MedTech Inc. (SMTI)vs › | $321.76M | 6.11 | 4.48 | 2.31 | 1.55 |
| Cabaletta Bio, Inc. (CABA)vs › | $329.37M | 0.12 | 0.17 | 0.10 | 0.07 |
| ClearPoint Neuro, Inc. (CLPT)vs › | $330.19M | 5.93 | 1.11 | 0.80 | 2.27 |
| C4 Therapeutics, Inc. (CCCC)vs › | $318.43M | 0.23 | 0.27 | 0.28 | 0.22 |
| Agenus Inc. (AGEN)vs › | $311.90M | N/A | 1.69 | 1.69 | 1.69 |
| Benitec Biopharma Inc. (BNTC)vs › | $309.19M | 0.00 | 0.01 | 0.70 | 0.51 |
| Relmada Therapeutics, Inc. (RLMD)vs › | $344.04M | 0.00 | 0.00 | 0.00 | 0.00 |
| Turn Therapeutics Inc. (TTRX)vs › | $346.73M | 8.91 | 0.02 | 0.15 | 0.15 |
Debt/Equity
0.05
Current Ratio
3.35
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.05 |
| 2026-03-31 | 0.04 |
| 2025-12-31 | 0.07 |
| 2025-09-30 | 0.05 |
| 2025-06-30 | -0.01 |
| 2025-03-31 | 0.13 |
| 2024-12-31 | -0.01 |
| 2024-09-30 | 0.00 |
| 2024-06-30 | 0.00 |
| 2024-03-31 | 0.00 |
